Everolimus for Treatment of Pseudomyogenic Hemangioendothelioma

被引：37

作者：

Ozeki, Michio ^{[1
]}

Nozawa, Akifumi ^{[1
]}

Kanda, Kaori ^{[1
]}

Hori, Tomohiro ^{[1
]}

Nagano, Akihito ^{[2
]}

Shimada, Akira ^{[4
]}

Miyazaki, Tatsuhiko ^{[3
]}

Fukao, Toshiyuki ^{[1
]}

机构：

[1] Gifu Univ, Grad Sch Med, Dept Pediat, Yanagido 1-1, Gifu 5011194, Japan

[2] Gifu Univ, Grad Sch Med, Dept Orthoped Surg, Gifu, Japan

[3] Gifu Univ, Grad Sch Med, Dept Pathol, Gifu, Japan

[4] Okayama Univ, Dept Pediat, Grad Sch Med, Okayama, Japan

来源：

JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY | 2017年 / 39卷 / 06期

关键词：

soft tissue tumor; vascular tumor; mammalian target of rapamycin (mTOR) inhibitor; kaposiform hemangioendothelioma (KHE); phosphoinositide-3-kinase (PI3K); PLASMINOGEN-ACTIVATOR INHIBITOR-1; SARCOMA-LIKE HEMANGIOENDOTHELIOMA; KAPOSIFORM HEMANGIOENDOTHELIOMA; CANCER; SIROLIMUS; PAI-1;

D O I：

10.1097/MPH.0000000000000778

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Pseudomyogenic hemangioendothelioma (PMH) is a recently described vascular neoplasm that occurs most commonly in the soft tissue of the distal extremities of young adults. Metastatic PMH can be fatal and there are no effective medications. We describe a case of a 15-year-old boy with metastatic PMH, who responded to treatment with everolimus, a mammalian target of rapamycin inhibitor. Immunohistochemistry showed that mammalian target of rapamycin was expressed in PMH biopsy specimens, which may explain the reduction in PMH tumor size following treatment.

引用

页码：E328 / E331

页数：4

共 50 条

[21] Ultrasonographic and pathological findings of pseudomyogenic hemangioendothelioma
Chen, Gui-Wu
Leng, Xiao-Ling
Liu, Shao-Ming
Liao, Xiao-Min
KAOHSIUNG JOURNAL OF MEDICAL SCIENCES, 2024, 40 (06): : 605 - 606
[22] Epithelioid Sarcoma-like Hemangioendothelioma (Pseudomyogenic Hemangioendothelioma) Response
Hornick, Jason L.
Fletcher, Christopher D. M.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2011, 35 (07) : 1088 - 1089
[23] Intracranial pseudomyogenic hemangioendothelioma: A case report
Xie, Shanshan
Wang, Xiao
Zhang, Yong
Cheng, Jingliang
ASIAN JOURNAL OF SURGERY, 2023, 46 (12) : 6067 - 6068
[24] Pseudomyogenic hemangioendothelioma: A misleading vascular tumor
Sassi, Farah
Sahraoui, Ghada
Charfi, Lamia
Jaidane, Olfa
Mrad, Karima
Doghri, Raoudha
INTERNATIONAL JOURNAL OF SURGERY CASE REPORTS, 2022, 99
[25] Pseudomyogenic hemangioendothelioma - A rare vascular tumor
Bartholomew, John R.
Tran, Michael
VASCULAR MEDICINE, 2020, 25 (01) : 93 - 94
[26] Pseudomyogenic hemangioendothelioma presenting as a penile lesion
Youssef, Reem
Davis, Jessica L.
Anderson, William J.
Acosta, Andres M.
VIRCHOWS ARCHIV, 2024, : 1157 - 1160
[27] The cytologic features of primary pseudomyogenic hemangioendothelioma of bone
Hatfield, Bryce S.
Smith, Steven C.
Boikos, Sosipatros A.
Sayeed, Sadia
DIAGNOSTIC CYTOPATHOLOGY, 2021, 49 (12) : 1261 - 1264
[28] Pseudomyogenic Hemangioendothelioma in the thumb - report of a rare case
Vieira, F. Sousa
Sa, D.
Coelho, A.
Vizcaino, J. R.
VIRCHOWS ARCHIV, 2022, 481 (SUPPL 1) : S345 - S346
[29] Pseudomyogenic hemangioendothelioma: a little-known tumor
Santos, Rui Pedro
Carvalho, Sofia
Gomes, Joana
Perdal, Joana
ACTA DERMATOVENEROLOGICA ALPINA PANNONICA ET ADRIATICA, 2018, 27 (04): : 225 - 229
[30] FOSB is a Useful Diagnostic Marker for Pseudomyogenic Hemangioendothelioma
Hung, Yin P.
Fletcher, Christopher D. M.
Hornick, Jason L.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2017, 41 (05) : 596 - 606

← 1 2 3 4 5 →